



HAL
open science

The Mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control

María Rodríguez-Muñoz, Pilar Sanchez-Blazquez, Ana Vicente-Sánchez,
Esther Berrocoso, Javier Garzon

► To cite this version:

María Rodríguez-Muñoz, Pilar Sanchez-Blazquez, Ana Vicente-Sánchez, Esther Berrocoso, Javier Garzon. The Mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. *Neuropsychopharmacology*, 2011, 10.1038/npp.2011.155 . hal-00665881

HAL Id: hal-00665881

<https://hal.science/hal-00665881>

Submitted on 3 Feb 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**The Mu-opioid receptor and the NMDA receptor associate in PAG neurons:
implications in pain control**

María Rodríguez-Muñoz², Pilar Sánchez-Blázquez^{1,2}, Ana Vicente-Sánchez¹, Esther Berrocoso^{2,3}, Javier Garzón^{1, 2*}

¹Neuropharmacology, Cajal Institute, CSIC, 28002 Madrid; ²CIBER of Mental Health (CIBERSAM), ISCIII, 28002 Madrid, and ³Department of Neuroscience, Faculty of Medicine, University of Cadiz 11003 Cadiz, Spain.

Running Title: Association Mu-opioid receptor-NMDA receptor

***Corresponding author:** Javier Garzón, Instituto Cajal, CSIC. Avd. Dr. Arce 37, 28002 Madrid, Spain. Tel: 34 91 5854733, Fax: 34 91 5854754.

E-mail: jgarzon@cajal.csic.es

Abstract

The capacity of opioids to alleviate inflammatory pain is negatively regulated by the glutamate-binding *N*-methyl-D-aspartate receptor (NMDAR). Increased activity of this receptor complicates the clinical use of opioids to treat persistent neuropathic pain. Immunohistochemical and ultrastructural studies have demonstrated the co-existence of both receptors within single neurons of the central nervous system, including those in the mesencephalic periaqueductal grey (PAG), a region that is implicated in the opioid control of nociception. We now report that mu-opioid receptors (MOR) and NMDAR NR1 subunits associate in postsynaptic structures of PAG neurons. Morphine disrupts this complex by protein kinase C (PKC)-mediated phosphorylation of the NR1 C1 segment and potentiates the NMDAR-calcium and calmodulin dependent kinase II (CaMKII), pathway that is implicated in morphine tolerance. Inhibition of PKC, but not protein kinase A (PKA) or G-protein receptor kinase 2 (GRK2), restored the MOR-NR1 association and rescued the analgesic effect of morphine as well. The administration of *N*-methyl-D-aspartic acid separated the MOR-NR1 complex, increased MOR serine phosphorylation, reduced the association of the MOR with G proteins, and diminished the antinociceptive capacity of morphine. Inhibition of PKA, but not PKC, CaMKII or GRK2, blocked these effects and preserved morphine antinociception. Thus, the opposing activities of the MOR and NMDAR in pain control affect their relation within neurons of structures such as the PAG. This finding could be exploited developing bifunctional drugs that would act exclusively on those NMDARs associated with MORs.

Keywords: Mu-opioid receptor; *N*-methyl-D-aspartate receptor; periaqueductal grey; pain; analgesia; receptor association.

Introduction

The glutamate N-methyl-D-aspartate receptor (NMDAR) is essential to the function of the nervous system, and therefore its de-regulation contributes to the pathophysiology of many neurological disorders. These include neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis (Lipton 2006), and mood disorders, such as schizophrenia and depression (Mechri et al. 2001; Maeng and Zarate, Jr. 2007). The persistent activation of NMDARs is also responsible for the neural changes accompanying different variants of neuropathic pain, including nerve-injury-induced neuropathy, diabetic neuropathy, chronic inflammatory pain, cancer pain, and postherpetic pain. In these conditions of persistent pain, mu-opioid receptor (MOR)-activating opioids do not provide efficacious relief (Chapman et al. 1994; Sigtermans et al. 2009). Thus, to treat neuropathic pain in the clinic, opioid doses must be substantially increased beyond those effective against nociceptive pain, and the relief is, in most cases, only partial. Neuropathic pain is characterized by tactile allodynia and hyperalgesia, which remit with drug treatments that block NMDAR function, e.g., ketamine, methadone, and memantine (Mizoguchi et al. 2009). Although drugs that block NMDAR channel permeation improve or prolong opioid analgesia in humans, because of their lack of selectivity for those receptors involved in nociception they produce a series of unacceptable drawbacks, such as drowsiness, hallucinations, and even coma (Palmer 2001). Therefore, opioids are usually combined with antidepressants, anticonvulsants, or sodium channel blockers to increase their clinical effectiveness (reviewed in Mizoguchi et al. 2009). Certainly, a better understanding of the cross-talk that operates between MOR and NMDAR to regulate

nociception would improve the efficacy and selectivity of therapies used to treat debilitating neuropathic pain.

The observation that MOR-acting opioids are of limited efficacy in neuropathic pain is supported by pharmacological and molecular studies indicating that morphine analgesia is under negative functional regulation by the NMDAR-neural nitric oxide synthase (nNOS) cascade (Inoue et al. 2003; Rodríguez-Muñoz et al. 2008). However, the relationship between MORs and NMDARs is bidirectional, and tolerance to morphine develops as a consequence of MOR-induced potentiation of NMDAR-CaMKII activity (Trujillo 2002; Garzón et al. 2008). Indeed, MOR-acting opioids regulate glutamate-activated NMDAR currents in different areas of the nervous system, including the thalamus (Narita et al. 2008), nucleus coeruleus (Koyama and Akaike 2008) brainstem-medulla (Chen and Huang 1991; Kow et al. 2002), and spinal dorsal horn neurons (Rusin and Randic 1991). Most relevantly, acute opioid administration increases NMDAR function in neurons with opioid receptors (Martin et al. 1997; Przewlocki et al. 1999).

Anatomical studies have shown that MORs and NMDARs co-localize in many regions of the CNS, including patches within spiny neurons of the caudate-putamen, the habenular nucleus, the spinal cord dorsal horn, the shells of the nucleus accumbens, and neurons of solitary tract nucleus. Importantly, these two receptors co-localize on single neurons within the CNS (reviewed in Trujillo 2002), and at the ultrastructural level both receptors show convincing co-localization (Glass et al. 2009). Specifically, the midbrain periaqueductal grey (PAG) is densely innervated by glutamatergic projections from the forebrain, and there is robust MOR-NMDAR co-localization in the dendrites and somata of ventrolateral PAG neurons (Commons et al. 1999; Narita et al. 2008). The PAG is of physiological relevance to the nociceptive

modulation network that operates both at the supraspinal level and through dorsal horn interneurons (Mansour et al. 1988; Marinelli et al. 2002). Deep brain stimulation targeting the PAG produces analgesia by the action of endogenous opioids on PAG MORs (Barbaro 1988). This therapy has successfully been used to treat intractable pain in humans, including phantom limb pain, post-herpetic neuralgia, and diverse neuropathies (Bittar et al. 2005; Owen et al. 2007).

Therefore, current literature convincingly demonstrates that the MOR and the NMDAR coexist at certain postsynapses and that both receptors show an electrophysiological interaction in individual neurons. Therefore, MOR-NMDAR cross-regulation in pain control could be consequence of their presence in the same neuronal compartment without ruling out that direct interaction occurs. This last possibility is of special interest because it would provide a suitable substrate to develop more specific regulators of MOR-NMDAR function. With this in mind, we assessed whether MORs and NMDARs establish an association in PAG synaptosomes and analyzed the manner in which their agonists, morphine and NMDA, and a series of serine/threonine kinases regulate this relationship.

Materials and Methods

Preparation and solubilization of the PAG synaptoneurosome-enriched fraction. MOR immunoprecipitation and co-precipitation of associated proteins.

Procedures involving mice strictly followed the guidelines of the European Community for the Care and Use of Laboratory Animals (Council Directive 86/609/EEC) and Spanish Law (RD 1201/2005) regulating animal research. The experimental protocols were reviewed and approved by the Committee for Animal Experimentation at the CSIC.

Experimental tissue was obtained from male albino CD1 mice (Charles River, Barcelona, Spain) weighing 22–27 g. For immunoprecipitation studies, the PAG from 8 mice were typically pooled. The assays were repeated at least twice on samples that had received an identical opioid treatment and were collected at the same interval post-opioid administration. The methods used to prepare the PAG synaptosomal fraction have been described elsewhere (Rodríguez-Muñoz et al. 2007a). The affinity purified IgGs against the extracellular domains of the MOR 2EL (205-216: MATTKYRQGSID; GenScript Co, NJ) and of the NMDAR NR1 subunit (483-496: KFGTQERVNNSNKK; Sigma-Genosys, Cambridge, UK) were labeled with biotin (Pierce #21217 & 21339). Pilot assays were carried out to optimize the amount of IgG and sample protein needed to precipitate the desired protein in a single run. Target proteins were then immunoprecipitated from solubilized membranes and resolved by SDS/polyacrylamide gel electrophoresis (PAGE) as previously described (Garzón et al. 2005a). The separated proteins were then transferred onto 0.2 µm PVDF membranes and probed with the selected antibodies in DecaProbe chambers (PR 150, Hoefer-GE, Barcelona, Spain).

To assess the morphine-induced serine phosphorylation of MORs, the existing protein interactions were disrupted under denaturing conditions prior to immunoprecipitation (Rodríguez-Muñoz et al. 2007a). Afterwards, MORs were detected with the MOR CT antibody, and phosphoserines were detected with a mouse monoclonal antibody (IgM, 1:1000; Calbiochem, clone 1C8 525281).

Detection of signaling proteins.

The specificity and efficacy of the antibodies used in immunoprecipitation assays from mouse brain synaptosomes have been addressed elsewhere (Garzón et al. 2005b; Rodríguez-Muñoz et al. 2010; Garzón et al. 2011). These antibodies fulfill the recommended criteria for use in western blotting as well (Saper and Sawchenko 2003). All the antibodies (see Supplementary Methods) were diluted in TBS + 0.05% Tween 20 (TTBS) and incubated with the PVDF membranes for 24 h at 6°C. The secondary antisera were incubated for 2-3 h and visualized with the Immobilon Western Chemiluminiscent HRP substrate (Millipore #WBKLS0100). Chemiluminescence was recorded with a Chemilmager IS-5500 (Alpha Innotech, San Leandro, CA). Densitometry was performed using Quantity One Software (Bio-Rad) and expressed as the mean of the integrated volume after subtracting the background (average optical density of the pixels within the object area/mm²).

Expression of C terminus sequences of MOR1, MOR1C, NR1(C0-C1-C2) and NR1(C0-C2) splice variants

The KRX/pFN2A-MOR1 (C-terminus), KRX/pET151-MOR1C (C terminus), KRX/pFN2A-NR1 (segments C0-C2) and NR1 (segments C0-C1-C2) strains were grown to an optical density of 0.5-0.6. IPTG (Promega, #V3955) and Rhamnose

(Promega, #L5701) were added at a final concentration of 1mM and 0.1%, respectively. After overnight induction at room temperature, the cells were collected by centrifugation and the pellets were kept at -20°C. The proteins were purified under native conditions with Ni-NTA- agarose columns (Invitrogen, Probond™ Purification System, #K850-01), or on glutathione-Sepharose 4B columns (Amersham Biosciences, #27-4570) previously equilibrated with 30 bed volumes of: 50 mM Tris-HCl (pH 8), 1mM EDTA, 150mM NaCl, 0.5% Tween 20, 1% Triton X-100. The retained fusion proteins were cleaved on the column with ProTEV protease (Promega, #V605A), collected and concentrated in a centrifugal filter device (10000 nominal molecular weight limit, Amicon Microcon YM-10 #42407, Millipore). The TEV protease was removed by immobilization on affinity resins (Amersham Biosciences, #17-0575-01).

Evaluation of MOR-NMDAR1 interactions

The interaction of the NR1 C terminal sequence C0-C1-C2 (100 nM) or its clipped C0-C2 sequence (100 nM) with C terminus MOR1 or MOR1C variants (100 nM) was studied. The NR1 proteins were incubated with 100 nM GST protein (Genscript; USA Z02039; negative control) or with GST-MOR sequences in 450 µL of HBS-EP buffer (10 mM HEPES, pH 7.4; 150 mM NaCl; 3 mM EDTA; 0.005% P20) and mixed by rotation for 30 min at room temperature. After the incubation, glutathione sepharose was added to these protein mixtures. The pellets obtained by centrifugation were washed three times and solubilized in 2 × Laemmli buffer. The presence of NR1 C terminal sequences was analyzed by western blotting using an antibody against the C2 segment (NMDAR1 C2, 1:500, ab6485).

Phosphorylation of the NR1 subunit of the NMDAR (C0-C1-C2, 100 nM) was performed in a 50 μ L reaction mixture containing 60 mM NaHEPES (pH 7.5), 3 mM $MgCl_2$, 3 mM $MnCl_2$, 3 μ M Na-orthovanadate, 1 mM DTT and 250 μ M ATP. The reaction was carried out at room temperature in the presence of 30 nM PKC γ , and it was terminated after 20 min by the addition of the PKC inhibitor Gö7874 (Calbiochem #365252) at a concentration of 5 μ M. The influence of PKC phosphorylation of NR1 C0-C1-C2 on its binding to the MOR was then determined as described above.

Surface Plasmon Resonance analysis.

Interactions were determined using a BIACORE X (GE Healthcare). NR1 C terminal sequences C0-C1-C2 or C0-C2 (50 μ g/mL) were coupled to channel two of CM5 sensor chips (GE, BR-1000-14) by amine coupling at pH 7.0 (GE, BR-1000-50); channel one acted as the blank. The sensor surface was equilibrated with HBS-EP buffer (GE, BR-1001-88). After passing the MOR1 C terminal sequence (75 μ L) over the sensor surface, the sensorgrams were collected at 25 °C with a flow rate of 5 μ L/min. The CM5 sensor chip was regenerated after each cycle with two 15 μ L pulses of 10 mM glycine given at a 30 s interval (pH 2.5, GE, BR-1003-56). Increasing analyte concentrations were studied, and the results were plotted using BIAevaluation software (v 4.1).

Cell culture and transfection. Chinese hamster ovary (CHO) cells were grown in Dulbecco's modified Eagle's medium, DMEM supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL streptomycin, 100 μ g/mL penicillin and 10% (v/v) fetal bovine serum at 37 °C and in an atmosphere of 5% CO_2 . Cells were transfected for 48 h at ~70% confluence using Lipofectamine 2000 (Invitrogen)

according to the protocol of the manufacturer. The cells were further incubated for 18-36 hours prior to testing for transgenic expression.

Bimolecular fluorescence complementation (BiFC) analysis. The plasmid pPD49.83 was used to generate two cloning vectors for BiFC analysis. The constructs containing the heat shock promoter, hsp-16.41, a Myc or hemagglutinin tag for detection of BiFC fusion proteins, a multiple cloning site for subcloning the gene of interest, a linker sequence and the N-terminal fragment of Venus truncated at residue 173 (VN173) or the C-terminal fragment of Venus starting at residue 155 (VC155), were a gift of Dr. Chang-Deng Hu at Purdue University (USA). Full length murine NR1 (C0-C1-C2) and MOR were subcloned in frame into pCE-BiFC-VN173 or pCE-BiFC-VC155 plasmids using standard cloning strategies. Fragments were amplified by PCR using the following primers, NR1: 5'-AGGA/AGCTTAGCACCATGCACCTGCTGACATTC-3' (forward) /5'-CGT/CTAGAGCGTCTCTGCTCTCCCTATGAC-3' (reverse) for the pCE-BiFC-VN173; and MOR 5'-CCGG/TCGACGCAAGCATTGAGAACCAAGGACA-3' (forward) / 5'-GGTAC/CGGATGGCGTGGGACCCAGTTTG-3 (reverse) for pCE-BiFC-VC155 plasmid. Samples were imaged on glass bottom plates (MatTek Co, USA) by confocal microscopy using a Leica DMIII 6000 CS confocal fluorescence microscope equipped with a TCS SP5 scanning laser.

Animals, intracerebroventricular injection and evaluation of antinociception

Male albino CD-1 mice weighing 22-25 g were used. The response of the animals to nociceptive stimuli was determined by the warm water (52°C) tail-flick test. Baseline latencies ranged from 1.5 to 2.2 s, and they were not significantly affected by the

kinase inhibitors used or their solvent. A cutoff time of 10 seconds was used to minimize the risk of tissue damage. Antinociception was expressed as a percentage of the maximum possible effect ($MPE=100 \times [\text{test latency}-\text{baseline latency}]/[\text{cutoff time}-\text{baseline latency}]$). Animals were lightly anaesthetized with ether and morphine sulphate (Merck, Darmstadt, Germany). Then, 15 pmol and 180 pmol NMDA (Tocris#01114), 1 nmol Gö7874 (Calbiochem, #365252), 15 nmol KN93 (Calbiochem #422711), 5 and 15 nmol PKA inhibitor 6-22 amide (Sigma-Aldrich #P6062) or 20 and 100 nmol β ARK1 inhibitor (Calbiochem #182200) were injected in a volume of 4 μ L into the lateral ventricle. Saline was likewise administered as a control. Antinociception was assessed at different time intervals thereafter.

The development of morphine-induced acute opioid tolerance was monitored 24 h after giving icv a priming dose of 10 nmol morphine. Thus, a dose-effect curve of morphine was constructed by determining analgesia 30 min after the injection of the opioid. This interval corresponds to morphine analgesic peak effect.

Statistical significance. ANOVA followed by the Student-Newman-Keuls test (SigmaStat, SPSS Science Software, Erkrath, Germany) was performed, and significance was defined as $P < 0.05$.

Results

MOR and NMDAR associate in mouse neuronal tissue.

NMDARs, which control a cation channel that is highly permeable to Ca^{2+} , are formed by a tetramer consisting of a pair of NR1 subunits associated with at least one type of NR2 (A, B, C, and D) or NR3 (A and B) subunit (Mori and Mishina 1995). To determine the existence of an association between MORs and NMDARs, we first analyzed whether they could be co-immunoprecipitated from mouse brain synaptosomes. In neuronal membranes the cytosolic regions of these two receptors interact with third partner proteins; thus, in the immunoprecipitation analysis, we used antibodies directed to extracellular domains of the MOR and NR1 subunits. Because MOR variants show differences in their cytosolic C terminus (Pan 2005), our approach would not distinguish among them. The MOR co-precipitated with NR1 subunits but showed little or no co-precipitation with NR2/3 subunits. This pattern was observed in the PAG, cerebral cortex, striatum, and dorsal spinal cord, but co-precipitation was almost absent from the cerebellum (Fig. 1A). Using an antibody against the NR1 extracellular peptide sequence, we determined that the NR1 subunit co-precipitated with MOR1 and MOR1C variants (Fig. 1B). NR1 subunits show variability in their distal C terminus and are classified as C2 and C2' (Zukin and Bennett 1995). The C terminus of the NR1 subunit is composed of C0-C1-C2(C2') regions, variants 011/111 and 010/110 respectively; however, some NR1 lack the C1 segment, C0-C2(C2'), variants 001/101 and 000/100 respectively. An *ex vivo* analysis of the NR1 subunits co-precipitated with the MORs indicated the presence of both C2 and C2' variants (Fig. 1C).

The MOR-NR1 association withstood solubilization by sonication-Nonidet p40 or RIPA buffer (Pierce, 89900), although it was destroyed by 1% SDS solubilization

buffer. Because SDS at this concentration prevents interactions between proteins, the presence of the ionic detergent was reduced with octylthioglucoside. The anti-MOR antibody subsequently captured the MOR without the associated NR1 subunit (Fig. 2A). This observation suggests that the MOR associates (directly or indirectly) with the NR1 subunit in the synaptic membrane, and when separated the mutual affinity displayed by these two proteins is probably occluded by the presence of third partner proteins. Therefore, MOR-NR1 co-precipitation is not a result of their interaction during the solubilization procedure and certainly suggests a functional role for this relationship.

Given the MOR-NR1 association in synaptosomal membranes, we next addressed whether these receptors physically interact in living cells. The Biomolecular Fluorescence Complementation (BiFC) approach is used for the detection of protein direct interactions in the normal cellular environment (Shyu et al. 2008). Thus, CHO cells were transfected with a mix (1:1) of plasmids expressing MOR1 coupled to VC155 and NR1 (C0-C1-C2) coupled to VN173 at the corresponding C termini. The physical interaction of the carrier proteins allows the VC155 and VN173 fragments to couple and form a stable fluorescent complex. Numerous cells displayed the fluorescent signal, indicating that MOR and NR1 can form a heterodimer *in vivo* (Fig. 2B). Because these VC and VN fragments are not fluorescent on their own, the cells that did not fluoresce were likely not transfected or were singly transfected with either the MOR1-VC155 or the NR1-VN173 construct.

Dopamine D1 receptors and group I metabotropic glutamate receptor 5a form complexes with NR1 subunits through their respective C termini (Fiorentini et al. 2003; Perroy et al. 2008). Accordingly, we determined the role of these protein regions in the interaction between MOR and NR1 (Supplemental Fig. 1). Using

surface plasmon resonance (SPR) analysis, which detects protein interactions during co-incubation, we observed a robust interaction between the MOR1 C terminus and the C1 region of the NR1 C terminus (Fig. 2C). *In vitro* co-incubation assays confirmed this pattern; the MOR1 and the MOR1C C termini bound the NR1 cytosolic sequence C0-C1-C2 but not NR1 C0-C2 (Fig. 2D). Serine residues in the C1 sequence, i.e., serines 890, 896 and 897, are implicated in the regulation of NMDAR function by PKC and PKA (Hisatsune et al. 1997; Tingley et al. 1997). The MOR1-NR1 direct binding was greatly diminished by the action of PKC γ on this critical C1 domain (Fig. 3). The analysis of the NR1 C-terminal sequence, C0-C1-C2 (DNASTAR, Protean v8.0.2), revealed a cluster of positively charged residues at the end of the C1 segment (889-898: SSFKRRRSSK) that could interact with the negative regions in the C terminus of MOR1 and MOR1C. Phosphorylation of these NR1 C1 serine residues reduces the positive charge, thereby weakening the association between MOR and NMDAR1. The isoelectric point shifts from 11.72 to 9.98 (P), 7.61 (P-P) and 6.8 (P-P-P) (ExpPASy's Compute pI/Mw).

Pharmacological recovery of opioid analgesia from tolerance.

The icv administration of morphine to mice produces a dose-dependent antinociceptive effect that reaches a maximum at about 30 min post-injection. The administration of a 10 nmol dose brings about a profound decrease in the response to successive doses of morphine that is a result of acute analgesic tolerance. The lower 3 nmol dose produces no single dose tolerance, indicating that the effects of morphine have to reach a certain threshold before desensitization is achieved (Rodríguez-Muñoz et al. 2007b). This single-dose (acute) tolerance can be detected 3 h after administration but is clearly observed when the analgesic dose-response

curve is assessed 6 h after the animals receive the initial priming dose of 10 nmol morphine. Therefore, this process requires time to develop (Rodríguez-Muñoz et al. 2007a). In our assay, the apparent ED₅₀ of icv morphine was 3.75 nmol/mouse (95% confidence limits: 2.85-4.90) for control mice and >10 nmol/mouse for mice pre-treated (24 h) with 10 nmol morphine. We then determined whether inhibition of the serine and threonine kinases PKC, PKA and GRK2 could restore morphine analgesic potency from the acute tolerant state. The mice received the priming dose of 10 nmol morphine. Twenty-four hours later, they were injected icv with 5 or 15 nmol of the PKA inhibitor 6-22 amide, 1 nmol of the PKC inhibitor Gö7874, 20 or 100 nmol of the GRK2 inhibitor iβARK1. The effect of increasing opioid test doses was assessed 30 min after the inhibitor injection. The dose of 20 nmol iβARK1 reverses antinociceptive tolerance in DAMGO-tolerant mice. However, doses up to 100 iβARK1 fail in recovering morphine from antinociceptive tolerance (Sánchez-Blázquez et al. 2008; Hull et al. 2010). On the other hand, 5 nmol of the PKA inhibitor 6-22 amide is effective in restoring morphine analgesia from NMDA antagonism (Fig. 7A). Therefore, given the suitability of the doses used for the kinase inhibitors we concluded that tolerant mice recovered their responses to morphine after PKC inhibition, but not after PKA or GRK2 inhibition (Fig. 4A).

Effect of morphine on the association between MOR and NR1: role of PKC.

For those cases in which receptor dimerization has been proposed, the formation of the complex usually affects the properties of each individual partner, particularly the capacity of agonists to promote receptor internalization. Therefore, we first determined the effect of *in vivo* administration of morphine on the stability of the PAG MOR-NMDAR association when analyzed *ex vivo*. In agreement with previous

reports (reviewed in Rodríguez-Muñoz et al. 2007a), a single icv dose of 10 nmol morphine promoted no significant changes in cell surface MORs. At the intervals at which morphine analgesia declined, but not before, the association of NR1 subunits with the MOR diminished (Fig. 4B). The NR1 subunits associated with MORs showed no serine phosphorylation, but in the membrane morphine increased the activating phosphorylation of NR1 serine 890 and of NR2A tyrosine 1325 as well as CaMKII autophosphorylation at threonine 286 (Fig. 4C). Morphine also diminished the association of the MOR with the postsynaptic marker PSD95 (Fig. 5A). These changes were accompanied with increases in MOR phosphorylation, decreases in MOR coupling to the regulated G proteins (Fig. 5B), and the onset of acute tolerance (Rodríguez-Muñoz et al. 2007a). A second dose of 10 nmol morphine given 24 h after the priming dose produced only weak analgesic effects, indicating that acute tolerance had developed (Fig. 4). Under these circumstances, morphine further reduced the number of MOR-NR1 complexes (Fig. 5B). All these molecular changes brought about by the icv dose of 10 nmol morphine were prevented by the co-administration of the MOR selective antagonist Cys², Tyr³, Orn⁵, Pen⁷-amide (CTOP; 0.6 nmol/mouse) (Gulya et al. 1988) (Supplemental Fig. 2).

Inhibition of PKC before the administration of this priming dose of morphine prevented serine phosphorylation of the MOR, and, consequently, the receptor maintained its control over G protein-mediated transduction. In these circumstances, morphine did not diminish the MOR-NR1 association, and no analgesic tolerance developed (Figs. 4 & 6A). In mice that had been rendered tolerant to morphine, administration of Gö7874 restored MOR function and morphine regained its analgesic potency within a few minutes. This positive effect was related to a series of molecular changes, such as reformation of the MOR-NR1 complexes,

dephosphorylation of MORs and recovery of MOR regulation over G proteins. Thus, the mice showed a full analgesic response to the second dose of morphine, but without separation of Gö7874-reformed MOR-NR1 complexes or internalization of MORs (Fig. 6B). Therefore, morphine-induced analgesic acute tolerance is mostly mediated by PKC activity on a series of signaling proteins. Inhibition of this kinase resets the system to the parameters observed before the administration of the morphine priming dose and prevents the opioid from inducing changes related to MOR desensitization.

We previously reported that i β ARK1, a GRK2 inhibitor, does not affect the development of morphine tolerance (Sánchez-Blázquez et al. 2008). We have now determined that GRK2 inhibition did not prevent morphine from inducing MOR-NR1 separation. Moreover, i β ARK1 did not reverse analgesic tolerance or promote MOR-NR1 re-association (Figs. 4 & 6C). Similarly, inhibition of PKA did not rescue morphine tolerance or stimulate the re-grouping of MOR with the NR1 subunit.

NMDAR activation reduces morphine analgesia and disrupts MOR-NR1 association by a PKA-dependent mechanism.

The icv administration of NMDA, an agonist that acts at the glutamate-binding site on the NR2 subunit, resulted in the loss of the capacity of morphine to produce antinociception (Fig. 7A). The NMDAR inhibitors MK801 (Tocris #0924) (Wong et al. 1986) and D-AP5 (Tocris #0106) (Olverman et al. 1984) icv-injected at 0.3 nmol 10 min before NMDA preserved morphine analgesia effects. Inhibition of PKC (1 nmol Gö7874), or GRK2 (100 nmol i β ARK1) did not alter the negative effect of NMDA on morphine analgesia. Moreover, the inhibitor of CaMKII activity, KN93 (Calbiochem #422711) used at 15 nmol, dose that prevents morphine acute tolerance (Sánchez-

Blázquez et al. 2008; Garzón et al. 2011), also failed against the antagonism of NMDA on morphine analgesia. However, in mice treated with the PKA inhibitor, NMDA did not alter morphine normal analgesic effect. Although NMDA did not promote a substantial reduction of MOR or NR1 subunits in the PAG synaptosomal preparation, it greatly increased the serine phosphorylation of the MOR and the uncoupling of the MOR from the regulated G proteins. These desensitizing changes were accompanied by reductions in MOR-NR1 co-precipitation (Fig. 7B). The direct effect of NMDA on the NMDAR promoted some activating autophosphorylation of CaMKII, although it hardly affected PKC-mediated serine phosphorylation of the NR1 subunit or Src-mediated tyrosine phosphorylation of NR2A/B (Fig. 7C). These NMDA-induced changes on MOR and NMDAR signaling were all prevented by the NMDAR antagonists MK801 (Supplemental Fig. 3) or D-AP5 (not shown). The inhibition of GRK2, CaMKII or PKC did not modify the NMDA-induced MOR-NR1 disruption. On the contrary, inhibition of PKA preserved the MOR-NR1 association (Fig. 7D).

Discussion

We have observed that metabotropic MORs and glutamate-driven ionotropic NMDARs are associated in different areas of the mouse CNS and that PKC and PKA regulate their relation. During recent years, different laboratories have convincingly described the functional cross-regulation of MORs and NMDARs in pain control. Moreover, anatomical studies, ultrastructural analyses and electrophysiological data have suggested that the opposing interaction of MORs and NMDARs could be achieved in the same neuron within a common cellular compartment. Although, it is complicated to ascertain the direct physical association of these two receptors in *in vivo* studies, however, we have provided *ex vivo* and *in vitro* data demonstrating that such an interaction is certainly possible. Notwithstanding, just the finding of the association between MORs and NMDARs is of relevance to the pharmacology of pain, particularly to the clinical management of opioid-resistant neuropathic pain. At the molecular level, various signaling proteins have been implicated in the bidirectional MOR-NMDAR regulation (Trujillo 2002; Garzón et al. 2008). In the framework of this MOR-NMDAR association, without ruling out the possibility of their physical interaction, those regulatory mechanisms have increased importance and provide the rationale to identify markers associated with increased nociception or therapeutic targets to control these dysfunctions.

The *ex vivo* analyses provided little information on the precise NR2/3 composition of MOR-associated NMDARs. However, our study provides information on the manner in which the MOR could interact with the NR1 subunit. *In vitro*, this association occurs through the respective C termini; the MOR binds to NR1 subunits carrying the C1 region but shows no interaction with NR1 subunits lacking the C1 segment. Moreover, the MOR co-precipitated with the PSD95, indicating that this

receptor associates with the NR1 splice variant that contains the sequence for anchoring to PSD95 in the C2' segment (Kornau et al. 1995). Therefore, MOR associates with NR1 subunits with a C terminus composed of C0-C1-C2(C2') regions. Interestingly, the few GPCRs that have been reported to associate with NMDARs interact with this NR1-containing C1 region. Indeed, the C termini of dopamine D1 receptor and of group I metabotropic glutamate receptor (mGlu5a) interact with the NR1 C1 terminal sequence (Fiorentini et al. 2003; Pei et al. 2004; Perroy et al. 2008). The binding of Ca^{2+} -calmodulin to this cytosolic region of NR1 negatively regulates calcium flux through NMDARs. Morphine stimulates the separation of the PAG MOR-NMDAR complex, probably via PKC acting on the C1 segment of the NR1 C terminus (Chakravarthy et al. 1999), and thus enhances NMDAR calcium permeation by preventing this inhibitory binding of Ca^{2+} -calmodulin.

Whereas, GRK2/3 controls the effects of MOR agonists, such as [D-Ala², N-MePhe⁴, Gly-ol⁵] enkephalin (DAMGO), which are strong inducers of receptor internalization (Hull et al. 2010), PKC, and to some degree PKA as well, has systematically been implicated in the development of tolerance to the analgesic effects of morphine which promotes low levels of MOR internalization (reviewed in Garzón et al. 2008). In the CNS, PKC through the potentiation of NMDAR function negatively regulates morphine analgesia but not that of DAMGO (Bilsky et al. 1996) (Lu et al. 1999; Sánchez-Blázquez et al. 2009). Therefore, morphine was used in this study because its antinociception is regulated by PKC and NMDAR activity. Our recent studies indicate that, via MOR-Gβγ-PI3K-Akt-nNOS, morphine stimulates the production of nitric oxide (NO) (Sánchez-Blázquez et al. 2010), which releases zinc ions from endogenous stores to recruit PKCγ and Raf-1 to the HINT1 protein at the MOR C terminus (Rodríguez-Muñoz et al. 2008; Rodríguez-Muñoz et al. 2011).

Then, PKC γ causes MOR-NR1 separation and produces the sustained potentiation of NMDAR calcium currents by activating Src (Sánchez-Blázquez et al. 2009), and also Raf-1-ERK1/2 cascade (Rodríguez-Muñoz et al. 2011). Afterwards, NMDAR-regulated CaMKII promotes MOR phosphorylation and its uncoupling from regulated G proteins (Sánchez-Blázquez et al. 2008 and references therein). The MOR-NMDAR association indicates that those concatenated processes are confined within the close environment of both receptors. PKA has also been implicated in the phosphorylation of NR1 C1 Ser897 (Tingley et al. 1997); however, our results indicate that morphine recruits PKC to separate both receptors in PAG neurons. In agreement with our observation, PKC phosphorylation of NR1 Ser890 promotes the dispersion of membrane NR1 subunits, which reorganize when they are dephosphorylated. This is not observed when Ser896 or Ser897 are phosphorylated (Tingley et al. 1997).

The PKC-mediated separation of MORs from NMDARs is observed when the analgesic efficacy of morphine declines. This phenomenon starts about 3 h to 6 h after the injection of icv morphine. Twenty-four hours later, some of the MORs in the synaptosomal membrane remain separated from NMDARs. This timing reasonably agrees with the PKC-mediated activation of ERK1/2 at MORs, which leads to enhancement of NMDAR function (Rodríguez-Muñoz et al. 2011). After MOR separates from the NMDAR, but not before, the administration of a second dose of morphine promoted GRK2-mediated phosphorylation of MOR Ser375, and these receptors then underwent internalization/recycling (Rodríguez-Muñoz et al. 2007a; present study). Therefore, NR1 separation from the MOR C terminus permits GRK2 to act on Ser/Thr residues required for internalization of the receptor. The recycling of the MOR did not help morphine to recover full analgesic potency, but brought no

further tolerance even after additional administrations of the opioid (Rodríguez-Muñoz et al. 2007a). Thus, MOR signaling was kept reduced by the effect of PKC-activated NMDARs, and accordingly in morphine-tolerant mice the inhibition of PKC caused MOR dephosphorylation and re-established MOR coupling to G proteins. The inhibition of PKC facilitated NR1 C1 dephosphorylation and probably also facilitated the inhibitory binding of Ca^{2+} -calmodulin to this region. Thus, morphine triggers a PKC activity which last longer than its analgesic effect. This durable activation of PKC seems to be mediated by the morphine-induced long-lasting enhancement of NMDAR function (Sánchez-Blázquez et al. 2009; Rodríguez-Muñoz et al. 2010). The NMDAR/nNOS-released zinc binds to the regulatory domain of conventional PKC isoforms and contributes to their activation. Then, zinc ions promote PKC translocation from the soluble phase to the membrane, enhances their affinity for phorbol esters or diacylglycerol and since high zinc stabilizes their binding the regulatory domain, PKC activation persists for long intervals (Zalewski et al. 1990; Rodríguez-Muñoz et al. 2008; Garzón et al. 2011). Indeed, this is not a singular event, in the NMDAR environment the long-term activation of PKA has also been reported this time related to transient inhibition of the protein serine/threonine phosphatase calcineurine (Malleret et al. 2001). As a whole, PKC inhibition reset the MOR-NMDAR system, reduced NMDAR function and restored the capacity of morphine to produce antinociception in mice that had been rendered tolerant to morphine. Similarly, NMDAR antagonists or CaMKII inhibitors also reverse morphine tolerance, but GRK2 inhibition does not (Sánchez-Blázquez et al. 2008; Hull et al. 2010). These observations suggest that the priming dose of morphine triggers a late negative feedback through MOR-stimulated NMDARs and causes acute morphine tolerance that diminishes the analgesia achieved with successive doses. Although

NMDARs are not involved in the regulation of analgesia produced by single doses of morphine or fentanyl in rodents, combinations of NMDAR antagonists with opioids seem to be effective to control pain in humans (Redwine and Trujillo 2003 and references therein). It is therefore possible that MOR-associated NMDARs are silent in most situations, but when the nociceptive signal reaches a certain threshold, as in situations of neuropathic pain, NMDAR activity negatively affects the signaling capacity of the MOR and then NMDAR antagonism is beneficial to opioid analgesia.

The pharmacological activation of NMDARs also caused separation of MOR and NR1 subunits and, importantly, stimulated the phosphorylation and uncoupling of MORs. Under these circumstances, NMDA administration greatly diminished the efficacy of morphine in controlling nociception, similar to what is observed in situations of neuropathic pain in which there is an NMDAR hyperfunction (Chapman et al. 1994; Celerier et al. 2000). There is a general agreement that PKA enhances NMDAR function in pain-suffering arthritic rats (Bird et al. 2005; Fu et al. 2008). We found that NMDA-induced antagonism of morphine antinociception could be prevented by inhibiting PKA but not PKC. Therefore, PKA may be responsible for the dissociation of NR1 subunits from MORs, which occurs as a result of NMDAR activation leading to MOR serine phosphorylation and uncoupling from G proteins. PKA located in the PSD-NMDAR complex is activated via Ca^{2+} -calmodulin dependent adenylyl cyclase and then potentiates NMDAR-dependent calcium currents (Chetkovich and Sweatt 1993). PKA does not affect NMDARs that contain NR1 subunits lacking the C1 region (Westphal et al. 1999). Therefore, the C1 segment of the NR1 subunit, which carries the inhibitory site for Ca^{2+} -calmodulin binding, is a common target for PKC and PKA phosphorylation. Then, NMDA-activated PKA enhances the NMDAR calcium fluxes necessary for CaMKII or nNOS

activation. Therefore, this mechanism would bring about a reduction in morphine-induced antinociception, in addition to the possibility of a direct effect of PKA on MOR cytosolic residues (Chakrabarti et al. 1998). In situations in which NMDARs, through PKA, and MORs, through PKC, contribute to opioid tolerance, the simultaneous inhibition of PKC and PKA would effectively restore the antinociceptive effect of morphine (reviewed in Garzón et al. 2008).

In summary, this study has shown that in the mouse PAG the MOR and the NMDAR form a PKC/PKA-regulated association, and that these receptors could physically interact. This association is altered by the functional antagonism that exists between MOR and NMDAR signaling in pain control. Thus, morphine and NMDA recruit PKC and PKA, respectively, to promote functional changes in the associated receptor-activating or inactivating phosphorylations. This MOR-NMDAR association appears to be of relevance in the control of nociception and provides a significant conceptual advance as to how the NMDAR exerts its negative regulation on MOR function. This finding could be useful in the clinical management of pain states refractory to opioid treatment; e.g., through the selectivity provided by bifunctional drugs that binding the MOR reach and antagonize the function of the associated NMDAR.

Disclosure/Conflict of Interest

The authors declare that, except for income received from our primary employer “Ministerio de Ciencia y Tecnología”, no financial support or compensation has been received from any individual or corporate entity over the past three years for research or professional service and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.

Acknowledgements

This research was supported by FIS PI080417 (PSB) and PS09/00332 (JG). MRM is currently supported by a CIBERSAM contract, and AVS is a pre-doctoral fellow from the Spanish Ministry of Science and Innovation. We thank Beatriz Fraile, Gabriela de Alba and Concha Bailón for their excellent technical assistance.

References

1. Barbaro NM (1988). Studies of PAG/PVG stimulation for pain relief in humans. *Prog Brain Res* **77**: 165-173.
2. Bilsky EJ, Inturrisi CE, Sadee W, Hruby VJ, Porreca F (1996). Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice. *Pain* **68**: 229-237.
3. Bird GC, Lash LL, Han JS, Zou X, Willis WD, Neugebauer V (2005). Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurones. *J Physiol* **564**: 907-921.
4. Bittar RG, Kar-Purkayastha I, Owen SL, Bear RE, Green A, Wang S, *et al.* (2005). Deep brain stimulation for pain relief: a meta-analysis. *J Clin Neurosci* **12**: 515-519.
5. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, *et al.* (2000). Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. *Anesthesiology* **92**: 465-472.
6. Chakrabarti S, Law PY, Loh HH (1998). Distinct differences between morphine- and [D-Ala²,N-MePhe⁴,Gly-ol⁵]-enkephalin-mu-opioid receptor complexes demonstrated by cyclic AMP-dependent protein kinase phosphorylation. *J Neurochem* **71**: 231-239.

7. Chakravarthy B, Morley P, Whitfield J (1999). Ca²⁺-calmodulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains. *Trends Neurosci* **22**: 12-16.
8. Chapman V, Haley JE, Dickenson AH (1994). Electrophysiologic analysis of preemptive effects of spinal opioids on N-methyl-D-aspartate receptor-mediated events. *Anesthesiology* **81**: 1429-1435.
9. Chen L, Huang LY (1991). Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a μ opioid. *Neuron* **7**: 319-326.
10. Chetkovich DM, Sweatt JD (1993). NMDA receptor activation increases cyclic AMP in area CA1 of the hippocampus via calcium/calmodulin stimulation of adenylyl cyclase. *J Neurochem* **61**: 1933-1942.
11. Commons KG, van Bockstaele EJ, Pfaff DW (1999). Frequent colocalization of μ opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons. *J Comp Neurol* **408**: 549-559.
12. Fiorentini C, Gardoni F, Spano P, Di LM, Missale C (2003). Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. *J Biol Chem* **278**: 20196-20202.
13. Fu Y, Han J, Ishola T, Scerbo M, Adwanikar H, Ramsey C, *et al.* (2008). PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. *Mol Pain* **4**: 26.

14. Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P (2005a). Activation of μ -opioid receptors transfers control of $G\alpha$ subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization. *J Biol Chem* **280**: 8951-8960.
15. Garzón J, Rodríguez-Muñoz M, Sánchez-Blázquez P (2005b). Morphine alters the selective association between mu-opioid receptors and specific RGS proteins in mouse periaqueductal gray matter. *Neuropharmacology* **48**: 853-868.
16. Garzón J, Rodríguez-Muñoz M, Sánchez-Blázquez P (2008). Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? *Curr Drug Abuse Rev* **1**: 222-238.
17. Garzón J, Rodríguez-Muñoz M, Vicente-Sánchez A, Bailón C, Martínez-Murillo R, Sánchez-Blázquez P (2011). RGSZ2 binds to the nNOS PDZ domain to regulate Mu-opioid receptor-mediated potentiation of the NMDAR-CaMKII pathway. *Antioxid Redox Signal* DOI: **10.1089/ars.2010.3767**.
18. Glass MJ, Vanyo L, Quimson L, Pickel VM (2009). Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala. *Neuroscience* **163**: 857-867.
19. Gulya K, Krivan M, Nyolczas N, Sarnyai Z, Kovacs GL (1988). Central effects of the potent and highly selective mu opioid antagonist D-Phe-Cys-Tyr-D-

- Trp-Orn-Thr-Pen-Thr-NH₂ (CTOP) in mice. *Eur J Pharmacol* **150**: 355-360.
20. Hisatsune C, Umemori H, Inoue T, Michikawa T, Kohda K, Mikoshiba K, *et al.* (1997). Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin. *J Biol Chem* **272**: 20805-20810.
21. Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, *et al.* (2010). The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. *J Pharmacol Exp Ther* **332**: 1127-1135.
22. Inoue M, Mishina M, Ueda H (2003). Locus-specific rescue of GluR ϵ 1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. *J Neurosci* **23**: 6529-6536.
23. Kornau HC, Schenker LT, Kennedy MB, Seeburg PH (1995). Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. *Science* **269**: 1737-1740.
24. Kow LM, Commons KG, Ogawa S, Pfaff DW (2002). Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO. *Brain Res* **935**: 87-102.
25. Koyama S, Akaike N (2008). Activation of mu-opioid receptor selectively potentiates NMDA-induced outward currents in rat locus coeruleus neurons. *Neurosci Res* **60**: 22-28.

26. Lipton SA (2006). Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. *Nat Rev Drug Discov* **5**: 160-170.
27. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, *et al.* (1999). G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. *Nat Neurosci* **2**: 331-338.
28. Maeng S, Zarate CA, Jr. (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. *Curr Psychiatry Rep* **9**: 467-474.
29. Malleret G, Haditsch U, Genoux D, Jones MW, Bliss TV, Vanhoose AM, *et al.* (2001). Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. *Cell* **104**: 675-686.
30. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988). Anatomy of CNS opioid receptors. *Trends Neurosci* **11**: 308-314.
31. Marinelli S, Vaughan CW, Schnell SA, Wessendorf MW, Christie MJ (2002). Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes. *J Neurosci* **22**: 10847-10855.
32. Martin G, Nie Z, Siggins GR (1997). mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons. *J Neurosci* **17**: 11-22.

33. Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L (2001).
Glutamnergic hypothesis of schizophrenia: clinical research studies with
ketamine. *Encephale* **27**: 53-59.
34. Mizoguchi H, Watanabe C, Yonezawa A, Sakurada S (2009). New therapy for
neuropathic pain. *Int Rev Neurobiol* **85**: 249-260.
35. Mori H, Mishina M (1995). Structure and function of the NMDA receptor
channel. *Neuropharmacology* **34**: 1219-1237.
36. Narita M, Hashimoto K, Amano T, Narita M, Niikura K, Nakamura A, *et al.*
(2008). Post-synaptic action of morphine on glutamatergic neuronal
transmission related to the descending antinociceptive pathway in the rat
thalamus. *J Neurochem* **104**: 469-478.
37. Olverman HJ, Jones AW, Watkins JC (1984). L-glutamate has higher affinity
than other amino acids for [3H]-D-AP5 binding sites in rat brain
membranes. *Nature* **307**: 460-462.
38. Owen SL, Green AL, Nandi DD, Bittar RG, Wang S, Aziz TZ (2007). Deep brain
stimulation for neuropathic pain. *Acta Neurochir Suppl* **97**: 111-116.
39. Palmer GC (2001). Neuroprotection by NMDA receptor antagonists in a variety
of neuropathologies. *Curr Drug Targets* **2**: 241-271.
40. Pan YX (2005). Diversity and complexity of the mu opioid receptor gene:
alternative pre-mRNA splicing and promoters. *DNA Cell Biol* **24**: 736-750.

41. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F (2004). Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. *J Neurosci* **24**: 1149-1158.
42. Perroy J, Raynaud F, Homburger V, Rousset MC, Telley L, Bockaert J, *et al.* (2008). Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. *J Biol Chem* **283**: 6799-6805.
43. Przewlocki R, Parsons KL, Sweeney DD, Trotter C, Netzeband JG, Siggins GR, *et al.* (1999). Opioid enhancement of calcium oscillations and burst events involving NMDA receptors and L-type calcium channels in cultured hippocampal neurons. *J Neurosci* **19**: 9705-9715.
44. Redwine KE, Trujillo KA (2003). Effects of NMDA receptor antagonists on acute mu-opioid analgesia in the rat. *Pharmacol Biochem Behav* **76**: 361-372.
45. Rodríguez-Muñoz M, de la Torre-Madrid E, Sánchez-Blázquez P, Garzón J (2007a). Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins. *Mol Pain* **3**: 19.
46. Rodríguez-Muñoz M, de la Torre-Madrid E, Sánchez-Blázquez P, Garzón J (2011). NO-released zinc supports the simultaneous binding of Raf-1 and PKC γ cysteine-rich domains to HINT1 protein at the Mu-opioid receptor. *Antioxid Redox Signal* **14**: 2413-2425.
47. Rodríguez-Muñoz M, de la Torre-Madrid E, Gaitán G, Sánchez-Blázquez P, Garzón J (2007b). RGS14 prevents morphine from internalizing Mu-

- opioid receptors in periaqueductal gray neurons. *Cell Signal* **19**: 2558-2571.
48. Rodríguez-Muñoz M, de la Torre-Madrid E, Sánchez-Blázquez P, Wang JB, Garzón J (2008). NMDAR-nNOS generated zinc recruits PKC γ to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. *Cell Signal* **20**: 1855-1864.
49. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Bailón C, Martín-Aznar B, Garzón J (2010). The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation. *Cell Mol Life Sci* DOI **10.1007/s00018-010-0598-x**.
50. Rusin KI, Randic M (1991). Modulation of NMDA-induced currents by mu-opioid receptor agonist DAGO in acutely isolated rat spinal dorsal horn neurons. *Neurosci Lett* **124**: 208-212.
51. Sánchez-Blázquez P, Rodríguez-Muñoz M, de la Torre-Madrid E, Garzón J (2009). Brain-specific G α_z interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. *Cell Signal* **21**: 1444-1454.
52. Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J (2010). Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. *PLoS One* **5**: e11278.
53. Sánchez-Blázquez P, Rodríguez-Muñoz M, Montero C, de la Torre-Madrid E, Garzón J (2008). Calcium/calmodulin-dependent protein kinase II

supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosphotyrosine-like protein. *Neuropharmacology* **54**: 319-330.

54. Saper CB, Sawchenko PE (2003). Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. *J Comp Neurol* **465**: 161-163.
55. Shyu YJ, Hiatt SM, Duren HM, Ellis RE, Kerppola TK, Hu CD (2008). Visualization of protein interactions in living *Caenorhabditis elegans* using bimolecular fluorescence complementation analysis. *Nat Protoc* **3**: 588-596.
56. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, *et al.* (2009). Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. *Pain* **145**: 304-311.
57. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, *et al.* (1997). Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. *J Biol Chem* **272**: 5157-5166.
58. Trujillo KA (2002). The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. *Neurotox Res* **4**: 373-391.
59. Westphal RS, Tavalin SJ, Lin JW, Alto NM, Fraser ID, Langeberg LK, *et al.* (1999). Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. *Science* **285**: 93-96.

60. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986).
The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Proc Natl Acad Sci U S A **83**: 7104-7108.

61. Zalewski PD, Forbes IJ, Giannakis C, Cowled PA, Betts WH (1990). Synergy
between zinc and phorbol ester in translocation of protein kinase C to
cytoskeleton. *FEBS Lett* **273**: 131-134.

62. Zukin RS, Bennett MV (1995). Alternatively spliced isoforms of the NMDAR1
receptor subunit. *Trends Neurosci* **18**: 306-313.

Figure legends

Figure 1. **MOR1 and NMDAR associate in the nervous system.**

Reciprocal co-precipitation of MOR and NR1 subunits from various areas of mouse central nervous system tissue. (A) Solubilized synaptosomes were incubated with biotinylated IgG directed to the second extracellular loop of the MOR (2EL). After being recovered with streptavidin-sepharose, the MOR-containing complexes were processed to remove the IgG before immunodetection of MOR1 and associated proteins (see Methods). For the PAG assay, the anti-NR1 antibodies used were the following: lane 1, Abcam ab1880, lane 2, Abcam ab28669, lane 3, Sigma-Genosys (482-456), lane 4, Abnova PAB12221. The antibodies used for detection of PAG NR subunits were: NR1, Abcam ab1880, NR2A, Abcam ab14596, NR2B, Abcam ab14400, NR2C, Abcam ab110, NR3AB, Abcam ab2639. The Abcam ab1880 antibody was used to detect MOR-associated NR1 derived from the other structures. (B) The Sigma-Genosys (482-456) antibody directed against the NR1 extracellular peptide sequence co-precipitated MOR1 (MOR CT antibody) and MOR1C (Neuromics #RA20001) variants. (C) To determine the NR1 variants associated with the MOR membrane proteins were solubilized, and the MOR was immunoprecipitated (IP) with affinity-purified IgG anti-MOR (2EL). The NR1 subunits that co-precipitated with MORs were recognized with antibodies directed to the NMDAR1 (ab1880), NMDAR1 C2 (ab6485) and NMDAR1 C2' (ab6486) regions of the NR1 subunit C terminus.

Figure 2. **Direct physical interaction of MORs with NMDARs: involvement of the C terminal sequences.**

(A) The membranes were solubilized, and the MOR was then immunoprecipitated (MOR 2EL antibody) to study the association between MOR and NR1 (MOR CT and ab1880 antibodies). Further details are provided in the Methods.

(B) BiFC analysis of the interaction between MOR1 and NR1. CHO cells were transiently co-transfected with cDNAs encoding NR1^{VN173} and MOR1^{VC155} (0.3 µg). The confocal fluorescent signals are obtained when two molecules of NR1^{VN173} and MOR1^{VC155} associate. Left: Phase field and fluorescent images are combined. Right: Fluorescent image of positive cells in the field.

(C) Surface plasmon resonance analysis of the MOR-NR1 interaction. The MOR1 C terminal sequence (287-399) interacts with the NR1 C terminus containing the C1 region. The sensorgrams were constructed with MOR1 Ct in the fluid phase at the concentrations (µg/mL) indicated. The NR1 C0-C2 produced no signal with the MOR1 C terminus.

(D) *In vitro* pull-down assays. NR1 C0-C1-C2 or NR1 C0-C2 C terminus variants were incubated with either the GST-MOR1C C terminus (337-439) (lane 1) or the GST-MOR1 C terminus (287-399) (lane 2). Both MOR1 C terminal sequences bind and co-precipitate with NR1 C0-C1-C2 but not with NR1 C0-C2. GST did not bind the NR1 C1 region (lane 3). P (captured and precipitated with glutathione sepharose); WB (anti-GST or anti-NR1 C2 region antibody).

Figure 3. Influence of PKC on the association of MOR1 and NR1 C termini.

The NR1 C0-C1-C2 sequence (100 nM) was exposed to PKC γ activity (30 nM). Western blot (WB) analysis revealed phosphorylation of serine 890, 896 and 897 located in the NR1 C1 segment. The GST-MOR1 C terminus (100 nM) was then incubated with 100 nM NR1 C0-C1-C2 that had or had not been exposed to active

PKC γ . GST-MOR1 Ct was then precipitated (P) with glutathione sepharose, and the associated NR1 was evaluated by WB using the anti-NR1 C2 antibody.

Figure 4. Effect of PKC, PKA and GRK2 inhibition on morphine-induced acute analgesic tolerance.

(A) Mice were icv-injected with 3 nmol or 10 nmol morphine, and antinociception was assessed with the warm water (52°C) tail-flick test. Each point is the mean \pm SEM from groups of 8 mice. The administration of a priming dose of 10 nmol morphine, but not 3 nmol, promoted acute analgesic tolerance. This was demonstrated by constructing a dose-effect curve for morphine 24 h after the mice received the priming dose. The pharmacological rescue from morphine-induced single-dose tolerance was studied. The PKC inhibitor Gö7874 (1 nmol), PKA inhibitor 6-22 amide (5 and 15 nmol), and GRK2 inhibitor i β ARK1 (20 and 100 nmol) were injected icv 30 min before constructing the morphine dose-effect curve. * Significantly different from the basal latencies obtained before the icv morphine injection; ϕ Significantly different from the value obtained in the absence of the priming dose of morphine, ANOVA-Student-Newman-Keuls test: $p < 0.05$.

(B) Morphine (10 nmol/mouse) reduced the association of NR1 subunits with MORs. The NR1 subunits were immunoprecipitated (IP) with the anti-NR1 antibody (ab1880), and the associated MORs were then evaluated by western blotting (anti-MOR CT). Representative blots are shown. NR1 was used as a loading control. The immunosignals (average optical density of the pixels within the object area/mm²; Quantity One Software, BioRad) were expressed relative to the levels of MORs observed in control mice that had not received morphine (given an arbitrary value of 1). Each data point represents the mean of three assays performed on PAG samples

obtained from independent groups of mice. Data are presented as the mean \pm SEM (Sigmaplot v11). * Significantly different from the value of 0m (controls that did not receive morphine), ANOVA-Student-Newman-Keuls test; $p<0.05$.

(C) Phosphorylations related to NMDAR-CaMKII activity were studied in the PAG membranes obtained from morphine-treated mice. The mice were administered 10 nmol morphine icv. The animals were then divided into groups of six mice and sacrificed at the post-opioid intervals indicated. The presence of NR1 and activating phosphorylations of NR1, NR2A and CaMKII was determined in the PAG synaptosomal membrane. The assay was repeated three times on samples derived from different groups of mice and the results were comparable.

Figure 5. Effect of repeated morphine administration on MOR-associated proteins.

Groups of mice received an initial icv dose of 10 nmol morphine. They then received a second dose of 10 nmol morphine or saline 24 h later. The mice were then sacrificed at the indicated time points. For each interval studied, the PAG structures from 6 mice were pooled for the *ex vivo* determinations. (A & B) The MOR was immunoprecipitated (IP) with the 2EL antibody, and the associated NR1, PSD95, and Gai2 proteins were evaluated. The MOR serine phosphorylation status was determined with the 1C8 clone after applying denaturing conditions to remove associated proteins that could mask the findings (see Methods). * Significantly different from the value of 0m (controls that did not receive morphine). Details are as in Fig. 4B.

Figure 6. Morphine promotes MOR-NR1 separation by a PKC-mediated mechanism.

(A) The PKC inhibitor Gö7874 (1 nmol), was injected icv to mice 30 min before the administration of 10 nmol morphine. At the intervals indicated, groups of 6 mice each were sacrificed, and the PAG was obtained for the *ex vivo* analysis. MOR was immunoprecipitated (IP) to determine its serine phosphorylation and association with NR1 and G α i2 subunits. (B) Mice that had received a priming dose of 10 nmol morphine icv were injected with 1 nmol Gö7874 icv 24 h later. After 30 min, the mice received a second test dose of 10 nmol morphine icv. *Significantly different from the value of 0m (controls that did not receive morphine; Fig. 7A). Details are as in (A). (C) Using the protocol of (B), the mice were injected with 100 nmol icv i β ARK1 30 min before the morphine test dose. Further details are in the Methods and the legend to Fig. 5.


Figure 7. Icv NMDA desensitizes the associated MOR and separates the MOR from the NR1 subunit.

(A) The injection of 15 pmol icv NMDA diminished the analgesic potency of morphine. The NMDAR antagonists MK801 and D-AP5 (0.3 nmol), the PKC inhibitor Gö7874 (1 nmol), PKA inhibitor 6-22 amide (PKA In, 5 nmol), CaMKII inhibitor KN93 (15 nmol), and GRK2 inhibitor i β ARK1 (100 nmol) were injected icv 10 min before NMDA. Then, morphine was icv-injected 20 min after NMDA and analgesia was evaluated 30 min post-opioid injection. ϕ Significantly different from the corresponding value of morphine analgesia obtained in the absence of the icv NMDA injection, ANOVA-Student-Newman-Keuls test: $p < 0.05$.



(B) Mice were injected with 15 pmol and 180 pmol icv NMDA, and groups of 6 mice each were sacrificed at the post-NMDA intervals indicated. The PAG was removed and pooled for the *ex vivo* studies. The MOR was immunoprecipitated (MOR 2EL antibody), and its serine phosphorylation (1C8 clone) was evaluated. The influence of NMDA on the association of G α i2 subunits and of NMDAR NR1 subunits was also determined. (C) Protein phosphorylation related to NMDAR-CaMKII activity was studied in PAG membranes obtained from NMDA-treated mice. (D) Effect of serine and threonine kinase inhibitors on NMDA-evoked separation of the MOR-NR1 complex. The mice received the inhibitors and 10 min later 15 nmol NMDA. The mice were sacrificed 20 min after receiving NMDA, and the PAG was removed and pooled for the *ex vivo* assays. Control mice received saline instead of the inhibitor or NMDA. The MOR was immunoprecipitated (IP), and the associated NR1 was measured. Further details are in the Methods and the legend to Fig. 4.

Figure 1

A




IP: MOR (PAG)



B

IP: NMDAR1 (PAG)



C




Figure 2










Figure 3





MOR1 Ct +
NR1/pSerNR1

P: GST-MOR1 Ct



A


Effect of serine/threonine kinase inhibitors on morphine-induced analgesic acute tolerance



- Morphine dose-effect (M d-e)
- Morphine (10 nmol) -24 h- (M d-e)
- Morphine -24 h- [1 nmol Gö7874 -30 m- (M d-e)]
- ◇ Morphine -24 h- [5 nmol PKA inhibitor 6-22 amide -30 m- (M d-e)]
- ◆ Morphine -24 h- [15 nmol PKA inhibitor 6-22 amide -30 m- (M d-e)]
- ⊙ Morphine -24 h- [20 nmol iβARK1 -30 m- (M d-e)]
- Morphine -24 h- [100 nmol iβARK1 -30 m- (M d-e)]

B

NR1-associated MOR: effect of morphine



C

Membrane




Figure 5





Figure 6






Figure 7

A NMDA reduces morphine analgesia: effect of serine/threonine kinase inhibition


Morphine, dose-effect (+ 30 min)




B 15 pmol 180 pmol NMDA



C Membrane



D IP: MOR



Supplemental figure 1

Mus musculus NMDA1 (zeta 1)(Grin1) 938aa: NM_008169, C terminus C0-C1-C2
901aa: AL732309.9, C terminus C0-C2

NR1-C0 (834-863) EIAYKRHKDARRKQMQLAFAAVNVWRKNLQ

NR1-C1 (864-900) DRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDT


NR1-C2 (901-938) STGGGRGALQNQKDTVLPRAIEREEGQLQLCSRHRES

Mus musculus MOR1 398aa: AB047546, C terminus (287-399)



VAVFIVCWTPIHIIYVIKALITIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFK
RCFREFCIPTSSTIEQQNSARIRQNTREHPSTANTVDRTNHQLENLEAETAPLP

Mus musculus MOR1 variant C 438aa: AF062753, C terminus (337-439)

YAFLDENFKRCFREFCIPTSSTIEQQNSARIRQNTREHPSTANTVDRTNHQPTLAV
SVAQIFTGYPSPTHVEKPKCKSCMDRGMRNLLPDDGPRQESGEGQLGR



B MOR-associated NR1: effect of morphine



Supplemental Figure 3

MK801 prevents the negative effect of NMDA on MOR function

